Investor Relations

Press Releases

 
Press Releases
  Date Title and Summary View
Mar 7, 2017
SAKURA Program Topline Results on Track to Report Fourth Quarter 2017 NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced the completion of pa...
Mar 3, 2017
- Additional Presentation Affirms Use of Patient Questionnaires in Assessing Frown Lines - NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today ...
Feb 27, 2017
- Cash and investments of $185.5 million as of December 31, 2016 - NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced results for the fourth ...
Feb 22, 2017
NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the company will participate in two upcoming investor conferences. Revance managem...
Feb 16, 2017
- Conference Call Scheduled for Monday, February 27, 2017 at 4:30pm ET - NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the...
Jan 26, 2017
- Poster Abstract at TOXINS 2017 Receives Honors - NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced presentation of clinical data from the ...
Jan 18, 2017
NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced presentations of clinical data for DaxibotulinumtoxinA Injectable (RT002) at TOXINS 2017, the Third Int...
Jan 5, 2017
- Reports 2016 Unaudited Year-end Cash and Investments Balance - - Three Clinical Trials Expected to Report Results in 2017 - NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aes...
Dec 12, 2016
- RT002 injectable appeared to be generally safe and well-tolerated - - RT002 injectable displayed clinically significant impact on cervical dystonia signs and symptoms - - Revance to host conference call at 4:30 pm ET today - NEWARK, Calif.--(BUSINESS WIRE)--...
Dec 7, 2016
- Topline Results of Pivotal Efficacy Trials Anticipated in Fourth Quarter 2017 - NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications,...
Page:
1
... NextLast
= add release to Briefcase
Shareholder Tools